YORK, Pa., Aug. 30, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced the development of a unique proprietary range of auto-injectors for ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...
Anaphylaxis is a serious, potentially life-threatening allergic reaction that can affect several organ systems in the body and may threaten breathing and blood circulation. The most common causes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback